Literature DB >> 31105859

Therapeutic effect of transplanted umbilical cord mesenchymal stem cells in a cynomolgus monkey model of multiple sclerosis.

Shijie Liu1,2, Jin Wang3, Rui Han1,2, Mingyao Meng1,2, Wenju Wang1,2, Yuan Zhao4, Fengmei Yang4, Li Yang5, Hui Gao1,2, Yiyi Zhao1,2, Lirong Yang1,2, Runqing Wang1,2, Weiwei Tang1,2, Yanyan Li4, Suqin Duan4, Junbing Wang4, Zhanlong He4, Lin Li1,2, Zongliu Hou1,2.   

Abstract

Multiple sclerosis (MS) is a demyelinating disease affecting 2.5 million young people worldwide because of its immune-mediated pathological mechanisms. Recent studies have shown that stem cell transplantation is a new potential therapy for MS. There has been renewed interest in cell therapy to improve quality of life for MS patients. In this study, the experimental autoimmune encephalomyelitis (EAE) model, which is the most commonly model to mimic MS, was successfully established in cynomolgus monkeys. To evaluate the therapeutic effect of human umbilical cord mesenchymal stem cells (UCMSCs) on MS, we intravenously transplanted UCMSCs into cynomolgus monkeys with EAE. Our results showed that UCMSC transplantation significantly ameliorated the clinical symptoms of MS. Magnetic resonance imaging and clinical signs indicated that demyelination was obviously decreased after UCMSCs therapy. Moreover, the present study showed that the mechanisms, involved in the effects of UCMSCs on MS, included their immunomodulatory functions to regulate cytokine secretion and affect functional differentiation of the T cell lineage.

Entities:  

Keywords:  Umbilical cord mesenchymal stem cells; cynomolgus monkey; multiple sclerosis; therapeutic effect

Year:  2019        PMID: 31105859      PMCID: PMC6511768     

Source DB:  PubMed          Journal:  Am J Transl Res            Impact factor:   4.060


  8 in total

Review 1.  Universal or Personalized Mesenchymal Stem Cell Therapies: Impact of Age, Sex, and Biological Source.

Authors:  Diana M Carp; Yun Liang
Journal:  Cells       Date:  2022-06-30       Impact factor: 7.666

Review 2.  Emerging Therapeutic Potential of Mesenchymal Stem/Stromal Cells in Preeclampsia.

Authors:  S Suvakov; C Richards; V Nikolic; T Simic; K McGrath; A Krasnodembskaya; L McClements
Journal:  Curr Hypertens Rep       Date:  2020-04-14       Impact factor: 5.369

Review 3.  The therapeutic applications of mesenchymal stromal cells from human perinatal tissues in autoimmune diseases.

Authors:  Chao Yang; Mingjun Wu; Min You; Yu Chen; Maowen Luo; Qiang Chen
Journal:  Stem Cell Res Ther       Date:  2021-02-04       Impact factor: 6.832

Review 4.  Research Progress on the Treatment of Premature Ovarian Failure Using Mesenchymal Stem Cells: A Literature Review.

Authors:  Jing Wang; Wanru Liu; Dehai Yu; Zongxing Yang; Sijie Li; Xiguang Sun
Journal:  Front Cell Dev Biol       Date:  2021-12-13

5.  Scrapie-Responsive Gene 1 Promotes Chondrogenic Differentiation of Umbilical Cord Mesenchymal Stem Cells via Wnt5a.

Authors:  Yuchuan Zhou; Tian Zheng; Lin Li; Yangfang Guo; Jiayu Xiao; Jin Wang; Zhiqin Du; Hui Gao; Weiwei Tang; Liusan Yang; Haiyan Hu; Xiaodan Wang; Mingyao Meng; Zongliu Hou
Journal:  Stem Cells Int       Date:  2022-01-27       Impact factor: 5.443

6.  Menstrual blood-derived mesenchymal stromal cells efficiently ameliorate experimental autoimmune encephalomyelitis by inhibiting T cell activation in mice.

Authors:  Yonghai Li; Haiyao Gao; Tobias M Brunner; Xiaoxi Hu; Yushan Yan; Yanli Liu; Liang Qiao; Peihua Wu; Meng Li; Qing Liu; Fen Yang; Juntang Lin; Max Löhning; Ping Shen
Journal:  Stem Cell Res Ther       Date:  2022-04-11       Impact factor: 6.832

Review 7.  Mesenchymal stem cell therapy: A review of clinical trials for multiple sclerosis.

Authors:  Asma Alanazi; Mohammad Alassiri; Dunia Jawdat; Yaser Almalik
Journal:  Regen Ther       Date:  2022-08-23       Impact factor: 3.651

Review 8.  Mesenchymal Stem Cells in Multiple Sclerosis: Recent Evidence from Pre-Clinical to Clinical Studies.

Authors:  Agnese Gugliandolo; Placido Bramanti; Emanuela Mazzon
Journal:  Int J Mol Sci       Date:  2020-11-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.